GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GRWD-5769’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GRWD-5769 overview
GRWD-5769 is under development for the treatment of solid tumors including head and neck squamous cell carcinoma, cervical cancer, and hepatocellular carcinoma. It acts by targeting endoplasmic reticulum aminopeptidase 1 (ERAP1). It is administered through oral route.
See Also:
Grey Wolf Therapeutics overview
Grey Wolf Therapeutics (Grey Wolf) is a pharmaceutical drug discovery and development biotechnology company. The company specializes in drug development for novel immuno-oncology therapies, and antigen presentation. Grey Wolf develops the small molecules that inhibit the endoplasmic reticulum aminopeptidases Endoplasmic Reticulum Associated Proteases (ERAP1, ERAP2), to identify the novel ERAP-inhibitor generated antigens and major histocompatibility complex class I (MHCI) directed therapies. Its service offering includes clinical trials, research and development, and drug discovery programs. The company has an operational presence in Australia. Grey Wolf is headquartered in Oxford, England, the UK.
For a complete picture of GRWD-5769’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
